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Highly Potent Antimicrobial Peptide Derivatives of Bovine 
Cateslytin 
T. M. Postma,a and R. M. J. Liskampa*
Antimicrobial peptides are potentially valuable antibiotics. More 
research is required to turn these compounds into viable 
therapeutics. Herein, a novel highly potent antimicrobial peptide 
is presented as a tool to study antimicrobial peptides. 
Antibacterial activity in the low micromolar range, low haemolytic 
activity and excellent serum stability were observed. 
Antibiotics form one of the pillars upon which modern 
medicine stands.1 This position has become threatened by the 
rapid rise of multidrug-resistant bacteria. In some clinical cases 
bacteria were identified that have become resistant to all 
known antibiotics, which is a serious global public health 
threat.2,3 There is an urgent need for new antibiotics with 
novel mechanisms that especially can be used to treat the 
clinically more relevant Gram-negative bacteria. Antimicrobial 
peptides (AMPs) are a first line of defence against microbial 
infection in humans and many other organisms.4,5 They are 
typically positively charged and therefore strongly interact 
with negatively charged bacterial membranes causing 
perturbation or pore formation.6–8 AMPs likely differentiate 
between bacterial and eukaryotic cells largely based on the 
difference in membrane composition. Bacterial membranes 
predominantly contain zwitterionic phosphatidylethanolamine 
together with up to 25% negatively charged phospholipids 
such as phosphatidylglycerol.9 Conversely, eukaryotic cells 
contain cholesterol and mostly phosphatidylcholine lipids, an 
essentially neutral zwitterionic outer membrane monolayer.10 
The mechanism of AMPs is very different from typical small 
molecule antibiotics and less prone to the induction of 
antimicrobial resistance.11 Moreover, the most attractive 
feature of AMPs is that they can circumvent antimicrobial 
resistance to small molecules by acting on the cell membrane, 
which can hardly be altered under the selection pressure of an 
antibiotic.12 Given the ubiquitous nature of AMPs in mammals 
and other organisms, there is high potential for an optimized 
peptide therapeutic to treat bacterial infections and more 
importantly infections of multidrug-resistant bacteria.13 
However, AMPs have not yet been successful as therapeutics 
and require more research to enable the design of high-
potential AMP drug candidates. This is partially caused by the 
challenge that a "membrane" as a target poses, as every cell 
has a membrane. Therefore, optimizing selectivity has become 
an important aspect to avoid any toxic side effects by 
antibiotic peptides. Herein, we report a novel highly potent 
and non-haemolytic peptide sequence as a new tool to study 
AMPs.  
 The parent sequence used in this study is based on the 
mammalian antimicrobial peptide cateslytin, part of the innate 
immune system, which is released by proteolytic cleavage 
from the protein chromatogranin A upon microbial 
infection.14,15 Chromogranin A can function as a pro-hormone 
with several bioactive peptide cleavage products that cover a 
wide range of functions in the cardiovascular, endocrine and 
immune systems.16 Chromogranin A is released from 
chromaffin cells upon stimulation of the adrenal gland or 
polymorphonuclear neutrophils.17 Cateslytin, a short 15 amino 
acid peptide, demonstrated activity against a range of Gram-
positive and Gram-negative bacteria, yeasts and fungi.18 
Dufourc and coworkers studied the interaction of cateslytin 
with bacterial and mammalian membrane mimics, which was 
found to act by a different mechanism compared to most 
AMPs.19,20 Cateslytin is unstructured in solution and forms 
antiparallel β–sheets upon interaction with a negatively 
charged bacterial membrane. The cateslytin antiparallel β–
sheets did not form pores but aggregated in negatively 
charged membranes to promote rigid domains that can disrupt 
membrane integrity leading to cell death. It is likely that this 
results in the selectivity of cateslytin for negatively charged 
bacterial cells over zwitterionic phospholipid containing more 
neutral membranes of mammalian cells.  
 Bovine cateslytin (RSMRLSFRARGYGFR) was significantly 
more potent than the human analogue (SSMKLSFRARGYGF) as  
Table 1: Synthesized antimicrobial peptides 
 
Peptide Amino Acid Sequence 
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1 (cateslytin) H-RSMRLSFRARGYGFR-OH 
2 H-RSMRLSFRARGYGFR-NH2 
3 H-RSL*RLSFRARGYGFR-OH 
4 H-RSL*RLSFRARGYGFR- NH2 
5 H-RSL*RLSWRARGYGFR- NH2 
6 H-RSL*RLSWRARGYGWR- NH2 
7 (synlytin) H-RTL*RLTWRARGYGWR- NH2 
Footnote: L* is norleucine 
 
it contains two additional positively charged arginine residue. 
A series of modified short peptide sequences of 15 amino acids 
were prepared using Fmoc solid-phase peptide synthesis 
(Table 1). The sequence of bovine cateslytin (1) contains a C-
terminal carboxylic acid which can potentially impact 
solubility, stability and activity. In the first cateslytin analogue 
the C-terminal carboxylic acid was changed into a C-terminal 
amide (2). Both cateslytin (1) and peptide 2 contain the amino 
acid methionine, which is prone to oxidation to methionine S-
oxide. Typically, methionine is often not critical for the activity 
of a peptide and can be exchanged by the unnatural amino 
acid norleucine. In this analogue, the methionine thioether 
moiety was replaced by a methylene unit. Therefore, two 
peptides were prepared with norleucine and either a C-
terminal carboxylic acid (3) or amide (4). In many cationic 
antimicrobial peptides the activity can be fine-tuned by 
altering the amphiphilic balance between charged and 
hydrophobic residues. To alter the amphiphilic properties of 
cateslytin several analogues were prepared. The phenylalanine 
residues were changed to either one (5) or two (6) tryptophan  
residues, a very common amino acid in antimicrobial 
peptides.21 The final peptide included an additional 
modification in which the amino acid serine was replaced for 
threonine to slightly alter the amphiphilic balance by addition 
of extra methyl groups (7).22   
 Following peptide synthesis the antibacterial activity was 
determined against a panel of clinically relevant bacteria 
(Table 2). The bacteria chosen for evaluation of the peptides 
were the Gram-negative Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Acinetobacter 
baumannii, and the Gram-positive Staphylococcus aureus and 
Staphylococcus epidermidis. Of these bacteria, five out of six 
are part of the “ESKAPE” pathogens.23 ESKAPE pathogens are a 
group of bacteria that are prone to antimicrobial resistance 
and therefore have a high clinical priority for the development 
of new antibiotics. The antibacterial activity was determined in 
a microbroth dilution assay to determine the minimum 
inhibitory concentration (MIC).24 The MIC is defined as the 
lowest concentration of an antibiotic that inhibits visible 
growth of bacteria as observed with the unaided eye.       
 Cateslytin (1) showed inhibition of bacterial growth with 
MIC values in the range of 4 to 32 µM for all Gram-negative 
and Gram-positive bacteria, with the exception of S. aureus. 
The MIC for S. aureus was higher than 128 µM. Changing the 
C-terminal carboxylic acid of cateslytin (1) into a C-terminal 
amide in peptide 2 resulted in a 2-fold increased potency for 
all bacteria except S. aureus. In peptide 3 methionine was 
replaced for norleucine, which caused a doubling in potency 
from cateslytin (1) and roughly the same as peptide 2. Peptide 
4 contained a C-terminal amide together with a norleucine 
residue that doubled the potency of peptide 3. However, the 
MIC for S. aureus stayed above 128 µM. Changing one of the 
phenylalanine residues into a tryptophan in combination with 
norleucine and a C-terminal amide significantly increased the 
potency for S. aureus in peptide 5 to an MIC of 32 µM. By 
changing both phenylalanine residues to tryptophan in peptide 
6 the potency increased 2-fold compared to peptide 5, except 
for S. aureus. The pronounced increase in potency after 
Table 2: Evaluation of peptide MIC values against Gram-negative and Gram-positive bacteria (µM)  
 
Bacterium Gram 1 2 3 4 5 6 7 Ampicillin 
Escherichia coli - 4 2 2 1 1 1 0.5 11 
Klebsiella pneumoniae - 8 2 4 2 4 2 1 168 
Pseudomonas aeruginosa - 32 8 8 4 8 4 2 21 
Acinetobacter baumannii - 32 16 16 8 16 8 4 5 
Staphylococcus aureus + >128 >128 >128 >128 32 32 16 337 
Staphylococcus epidermidis + 32 4 8 2 4 2 1 84 
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introducing tryptophan residues may be largely due to the 
following. Cateslytin and derivatives are rich in arginine with 5 
amino acid residues in a 15-peptide. As many antimicrobial 
peptides are remarkably rich in both arginine and tryptophan 
residues, the phenylalanine residues were replaced by 
tryptophan.25 The indole sidechain of tryptophan may interact 
with the cationic guanidino group of arginine. These groups 
can form a parallel cation - π interaction in which arginine 
retains the ability to hydrogen bond with other molecules.26 Of 
course many cation - π interactions can take place between 
cationic and aromatic amino acids, but tryptophan offers a 
much larger and stronger region of negative electrostatic 
potential, which would make tryptophan overall a better 
cation binding site than phenylalanine or tyrosine.27 
Furthermore, this interaction shields cationic arginine residues 
from the hydrophobic environment inside the lipid bilayer and 
may facilitate membrane entry by an antimicrobial peptide.28 
These properties of both arginine and tryptophan containing 
antimicrobial peptides may be responsible for the increased 
antibacterial activity observed with peptides 5 and 6. A similar 
potentiation was observed with a tryptophan and arginine 
containing 15 residue lactoferricin derivatives, where a 
substitution for tryptophan in position 8 resulted in a 6-fold 
increase in antibacterial activity against E. coli.29 An additional 
modification, in which the serine residues were replaced with 
threonine, resulted in the most potent peptide (7) in this 
series. Overall, the amphiphilic balance of cateslytin was 
gradually shifted to an increased hydrophobicity by the 
modifications. Increasing hydrophobicity in an antimicrobial 
peptide may result in more potent antibacterial activity 
although this can greatly increase haemolysis.30 Therefore, the 
serine residues were changed to threonine as this only gave a 
mild increase in hydrophobicity. Peptide 7 demonstrated 
potent inhibition of bacterial growth with MIC values between 
0.5 and 16 µM for all bacteria tested. With an MIC value of 16 
µM against S. aureus peptide 7 was significantly more potent 
than the parent sequence cateslytin (1) with an MIC of >128 
µM against this strain. Altering the amphiphilic balance of 
cateslytin by several modifications in the peptide sequence 
resulted in a very potent antimicrobial peptide that was active  
 
Table 4: Percentage haemolysis at 128 µM 
 
Peptide Percentage haemolysis 
1 (cateslytin) 
0 ± 0.1 
2 1.1 ± 0.4 
3 n.d. 
4 0.3 ± 0.1 
5 0.4 ± 0.4 
6 0.4 ± 0.1 
7 (synlytin) 0.3 ± 0.1 
Footnote: n.d. is not determined 
 
against both Gram-negative and Gram-positive bacteria. All 
peptides were significantly more potent than the antibiotic 
ampicillin, which was used as a control. 
 To further demonstrate the utility of the most potent 
synthetic cateslytin analogue 7, referred to as "synlytin", it was 
compared to cateslytin (1) against several drug resistant 
bacteria. Two strains of A. baumannii were used with 
mutations in LpxA (AL1851) and LpxD (AL1852).31,32 Mutations 
in the LpxA/D acetyltransferases halt early lipid A biosynthesis, 
which results in a lipopolysaccharide deficiency that causes 
resistance against polymyxin E. Two drug resistant strains of P. 
aeruginosa with high resistance against β–lactam antibiotics 
were used. The final strain used to demonstrate activity 
against resistant bacteria was a β–lactam resistant strain of 
Pandoraea apista, an emerging pathogen in respiratory 
infections.33 The MIC values of peptides 1 and 7 against these 
resistant bacteria were determined (Table 3).  
 Cateslytin (1) inhibited growth at 8 and 4 µM for the 
lipopolysaccharide deficient A. baumannii strains. Synlytin (7) 
was 4-fold more potent than cateslytin (1) and inhibited 
growth of A. baumannii strains at 2 and 1 µM. In both P. 
aeruginosa strains, cateslytin (1) did not inhibit growth within  
Table 3: Evaluation of peptide MIC values against drug-resistant bacteria (µM) 
 
Bacterium Gram 1 7 Polymyxin E Ampicillin 
A. baumannii (AL1851) - 8 2 3 3 
A. baumannii (AL1852) - 4 1 >400 3 
P.aeruginosa (TP161) - >128 8 0.2 >1346 
P.aeruginosa (TP162) - >128 4 0.2 >1346 
P. apista (TP163) - 8 0.5 6 >1346 
 
Journal Name  
COMMUNICATION 
 J. Name., 2013, 00, 1-3 | 4  
Please do not adjust margins 
Please do not adjust margins 
 
Figure 1: Serum stability of cateslytin (1) and synlytin (7) 
 
the concentration range tested with an MIC >128 µM. In 
contrast, synlytin (7) inhibited the growth of the P. aeruginosa 
strains at 8 and 4 µM. In the β–lactam resistant P. apista 
strain, cateslytin (1) gave an MIC of 8 µM, whereas synlytin (7) 
was 16 times more potent with an MIC of 0.5 µM. There 
results demonstrate that synlytin (7) is a significantly more 
potent antimicrobial peptide than cateslytin (1).  
 Antimicrobial peptides may show severe cytotoxicity to red 
blood cells. This toxicity is caused by the amphiphilic nature of 
most cationic peptides, which can act as potent cationic 
detergents. Lysis of red blood cells is an unacceptable form of 
toxicity in antimicrobial peptides and therefore must be 
quantified in a haemolytic assay. A wide range of haemolytic 
tendencies in studied antimicrobial peptides has been 
observed such as the highly toxic non-selective peptides 
mastoparan B (96% haemolysis at 30 µM) and melittin (100% 
haemolysis at 10 µM) or less toxic peptides that are more 
selective to bacterial cells like magainin 2 (50% haemolysis at 
428 µM) and HHC10 (only 0.4% haemolysis at 15.6 µg/mL).34–37 
The haemolytic activity of peptides 1-7 was determined using a 
haemolytic assay developed in our group with minor 
modifications (Table 4).37 In this assay sheep erythrocytes 
were used as a convenient source of red blood cells. 
 All evaluated peptides showed very little haemolysis even 
at 128 µM, which is 8 – 256 times higher than the MICs for the 
evaluated bacteria, when compared to 100% haemolysis (1% 
Triton X-100). At this concentration most peptides caused less 
than 1% haemolysis. These results clearly show that all 
cateslytin derivatives are not haemolytic even at a high 
concentration. 
 Peptides can be very unstable in human serum due to 
degradation by proteases. Therefore, the serum stability of 
cateslytin (1) and the most potent peptide synlytin (7) was 
determined by a method used previously in our group.38 
Human serum was used to evaluate the stability of the 
peptides for up to 24h at 37 °C (Figure 1). 
 Both cateslytin (1) and synlytin (7) showed excellent serum 
stability, cateslytin demonstrated a slightly better stability, 
with over 60% of the peptides remaining after 24h.  Cateslytin 
was reported to be stable to Staphylococcus aureus proteases 
by Metz-Boutigue and co-workers.15 The proteolytic stability of 
cateslytin (1) and synlytin (7) may be explained by cateslytin 
itself, since it is the final cleavage product of extensive 
proteolytic processing of chromogranin A and therefore it is 
probably less sensitive to further proteolytic degradation.  
Conclusions 
A series of bovine cateslyin derivatives were synthesized and 
the biological activity was evaluated. All peptides showed 
antimicrobial activity against Gram-negative and Gram-positive 
bacteria in the micromolar range. Synlytin (7) demonstrated 
the highest antimicrobial activity against a panel of clinically 
relevant bacteria. Cateslytin (1) and synlytin (7) were 
evaluated against several drug resistant bacteria, in which 
synlytin (7) was found significantly more potent than cateslytin 
(1). Cateslytin (1) and synlytin (7) demonstrated low 
haemolytic activity at even high concentration and excellent 
serum stability. These results clearly show that synlytin (7) is a 
superior AMP compared to the parent cateslytin (1) in terms of 
potency against Gram-negative, Gram-positive and drug-
resistant bacteria while remaining non-haemolytic and serum 
stable.  
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